Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant

Virology

Volumn 380, Issue 2, 2008, Pages 412-420

  Prabakaran, Mookkan ^a   Velumani, Sumathy ^a   He, Fang ^a   Karuppannan, Anbu K ^a   Geng, Grace Yuhong ^b   Yin, Lee Ker ^b   Kwang, Jimmy ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Cellbiotech Co Ltd   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

H5N1 influenza; Hemagglutinin; Mucosal vaccine; rCTB; Recombinant baculovirus

Indexed keywords

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; RECOMBINANT BACULOVIRUS SURFACE DISPLAYED HEMAGGLUTININ; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; BODY WEIGHT; CHOLERA TOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

AVES; MUS;

EID: 53449091640     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.08.002     Document Type: Article

References (29)

1. Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Matsuura Y., and Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J. Immunol. 171 (2003) 1133-1139
2. Beck N.B., Sidhu J.S., and Omiecinski C.J. Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes. Gene Ther. 7 (2000) 1274-1283
3. Bright R.A., Shay D.K., Shu B., Cox N.J., and klimov A.I. Adamantane resistance among influenza A (H3N2) viruses isolated early during the 2005-2006 influenza season in the United states. JAMA 295 (2006) 891-894
4. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., and Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3 1 (2008) e1501
5. Centers for Disease Control and Prevention (U.S.), and National Institutes of Health (U.S.). Biosafety in Microbiological and Biomedical Laboratories. 4th ed (1999), U.S. Dept. of Health and Human Services Public Health Service Centers for Disease Control and Prevention; National Institutes of Health;For sale by the Supt. of Docs. U.S. G.P.O., Washington [Bethesda, Md.].Washington, D.C
6. Fielding R., Bich T.H., Quang L.N., Lam W.W., Leung G.M., Tien T.Q., Ho E.Y., and Anht le.V. Live poultry exposures, Hong Kong and Hanoi. Emerg. Infect. Dis. 13 (2007) 1065-1067
7. Goto N., Maeyama J., Yasuda Y., Isaka M., Matano K., Kozuka S., Taniguchi T., Miura Y., Ohkuma K., and Tochikubo K. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 18 (2000) 2164-2171
8. Gronowski A.M., Hilbert D.M., Sheehan K.C.F., Garotta G., and Schreiber R.D. Baculovirus stimulates antiviral effect in mammalian cells. J. Virol. 73 (1999) 9944-9951
9. Isaka M., Yasuda Y., Kozuka S., Miura K., Taniguchi T., Matano K., Goto N., and Tochikubo K. Systemic and mucosal immune responses of mice to aluminium adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine 16 (1998) 1620-1626
10. Isaka M., Yasuda Y., Mizokami M., Kozuka S., Miura K., Taniguchi T., Matano K., Maeyama J., Mizuno K., Morokuma K., Ohkuma K., Goto N., and Tochikubo K. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19 (2001) 1420-1466
11. Isaka M., Komiya T., Takahashi M., Yasuda Y., Taniguchi T., Zhao Y., Matano K., Matsui H., Maeyama J., Morokuma K., Ohkuma K., Goto N., and Tochikubo K. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22 (2004) 3061-3068
12. Isaka M., Zhao Y., Nobusawa E., Nakajima S., Nakajima K., Yasuda Y., Matsui H., Hasegawa T., Maeyama J., Morokuma K., Ohkuma K., and Tochikubo K. Protective effect of nasal immunization of influenza hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Micrbiol. Immunol. 52 (2008) 55-63
13. Kreijtz J.H.C.M., Suezer Y., Amerongen G.V., and Mutsert G.D. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195 (2007) 1598-1606
14. Lu L., Yu L., and Kwang J. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem. Bioph. Res. Co. 358 (2007) 404-409
15. Maeyama J., Isaka M., Yasuda Y., Matano K., Taniguchi T., Morokuma K., Ohkuma K., Tochikubo K., and Goto N. Effects of recombinant cholera toxin B subunit on IL-1B production by macrophage in vitro. Microbial. Immunol. 46 (2002) 593-599
16. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., and Zambon M.C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines againstH5N1 influenza. Lancet 357 (2001) 1937-1943
17. Ogra P.L., Faden H., and Welliver R.C. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14 (2001) 430-445
18. Quan F., Huang C., Compans R.W., and Kang S. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81 (2007) 3514-3524
19. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938) 493-497
20. Safdar A., Rodriguez M.A., Fayad L.E., Rodriguez G.H., Pro B., Wang M., Romaguera J.E., Goy A.H., Hagemeister F.B., McLaughlin P., Bodey G.P., Kwak L.W., Raad I.I., and Couch R.B. Dose-related safety and immunogenicity of Baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J. Infect. Dis. 194 (2006) 1394-1397
21. Sminia T., and Kraal G. Nasal associated lymphoid tissue. In: Ogra P., Mestecky J., Lamm M., Strober W., Bienenstock J., and McGhee J. (Eds). Mucosal Immunology (1999), Academic Press, San Diego, California 357-364
22. Suguitan Jr. A.L., McAuliffe J., Milis K.L., Jin H., Duke G., Lu B., Luke C.J., Murphy B., Swayne D.E., Kemble G., and Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross protection in mice and ferrets. PLoS Med. 3 9 (2006) e360
23. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., and Katz J.M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
24. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., Holden-Wiltse J., Liang H., Gilbert A., and Cox M. Safety and immunogenicity of a baculovirus expressed hemagglutinin influenza vaccine. JAMA 297 (2007) 1577-1582
25. Wang M., Bregenholt S., and Petersen J.S. The cholera toxin B subunit directly co-stimulates antigen-primed CD4+ T cells ex vivo. Scand. J. Immunol. 58 (2003) 342-349
26. Webster R.G., Kawaoka Y., Taylor J., Weinberg R., and Paoletti E. Efficacy of nucleoprotein and hemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9 (1991) 303-308
27. World Health Organization. Laboratory Biosafety Manual. 3rd ed (2004), World Health Organization, Geneva
28. Wu H.Y., Nguyen H.H., and Russell M.W. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand. J. Immunol. 46 (1997) 506-513
29. Yuki Y., and Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13 (2003) 293-310